Quantcast

Latest Anxiolytics Stories

2010-02-04 08:01:00

SAN ANTONIO, Feb. 4 /PRNewswire-USNewswire/ -- Research presented at the American Academy of Pain Medicine's 26th Annual Meeting provides early published data analyzing information gathered from California's prescription monitoring program, known as the Controlled Substances Utilization Review and Evaluation System (CURES). The analysis found a two-fold increase in the likelihood of individuals receiving opioids from multiple providers or "doctor shopping" when they were also being...

2010-01-27 10:21:44

Chronic and severely stressful situations, like those connected to depression and posttraumatic stress disorder, have been associated with smaller volumes in "stress sensitive" brain regions, such as the cingulate region of the cerebral cortex and the hippocampus, a brain region involved in memory formation. A new study, published by Elsevier in Biological Psychiatry, suggests that chronic insomnia may be another condition associated with reduced cortical volume. Using a specialized technique...

2009-12-08 07:04:00

BEVERLY HILLS, Calif., Dec. 8 /PRNewswire/ -- The Waismann Method, a pioneering medical opiate detoxification procedure, offers one of the most advanced medical procedures worldwide with the medical expertise and advanced technology to treat dependencies to Zolpidem, a prescription medication widely used for the short-term treatment of insomnia and prescribed under trade names including Ambien and Edluar. The Waismann Method of Rapid Ambien Detox involves a safe, medically-assisted...

2009-11-23 17:03:27

Older adults who take several types of psychotropic medications"”such as antidepressants or sedatives"”appear more likely to experience falls, according to an analysis of previous studies reported in the November 23 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. More than 30 percent of individuals older than 65 will fall at least once a year, and falls and their complications are the fifth-leading cause of death in the developed world, according to...

2009-11-23 15:05:00

POINT RICHMOND, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the Complete Response Letter regarding the New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet). As previously announced, the Complete Response Letter, received by Transcept on October 28, 2009, indicated that the FDA...

2009-10-29 00:13:00

RICHMOND, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals (Nasdaq: TSPT) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter regarding the New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet). The NDA, submitted by Transcept in September 2008, seeks approval to market Intermezzo® for use as-needed for the treatment of insomnia when a middle of the night...

917469fd509ba84ce2bb795a1761564a1
2009-10-23 06:50:00

U.S. drug labels often omit key information about a medicine's effectiveness and the severity of its side effects, according to a commentary written by two doctors in the New England Journal of Medicine. Such omission of data can result in some medicines appearing safer and more effective than they actually are, wrote Drs. Lisa Schwartz and Steven Woloshin of the Dartmouth Institute for Health Policy and Clinical Practice in Hanover, New Hampshire. "The most direct way that the FDA...

2009-10-22 06:00:00

REDWOOD CITY, Calif., Oct. 22 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical trial of ARX-03, a proprietary sublingual dosage form combining an opioid, sufentanil, with a benzodiazepine, triazolam. ARX-03 is designed to address the current unmet need for a non-invasive product to provide mild sedation, anxiolysis and analgesia with rapid onset of action for the increasing number of painful and anxiety-producing office-based...

2009-09-08 09:30:00

SOMERSET, N.J., Sept. 8 /PRNewswire/ -- Meda Pharmaceuticals Inc. (Meda) today announced the commercial availability of EDLUAR(TM) (zolpidem tartrate sublingual tablets) in the United States. EDLUAR is indicated for the short-term treatment of insomnia characterized by difficulties with falling asleep. EDLUAR is the first available under-the-tongue formulation of zolpidem tartrate, which is the most prescribed treatment for insomnia. Zolpidem tartrate is also the active ingredient in...

2009-09-03 03:00:00

BATH, England, September 3 /PRNewswire/ -- - Catalyst has Successfully Advised Accelerator Member EVRS Ltd on the Completion of GBP600,000 "Series A" Financing Provided by a Group of Private Investors EVRS has developed a new approach to waste recycling. The EVRS approach combines a well understood hydrolysis process with proprietary additives and catalysts to rapidly convert all organic matter into pure cellulose. The outputs from this process can either be utilised as a basis...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'